Experienced in EGFR Positive Lung Cancer

Nuran Katgi

Dr. Suat Seren Chest Diseases And Surgery Training And Research Hospital
Izmir, TR 
Experienced in EGFR Positive Lung Cancer
Dr. Suat Seren Chest Diseases And Surgery Training And Research Hospital
Izmir, TR 
OverviewLocationsClinical Research

Overview

Nuran Katgi practices in Izmir, Turkey. Ms. Katgi is rated as an Experienced expert by MediFind in the treatment of EGFR Positive Lung Cancer. Her top areas of expertise are EGFR Positive Lung Cancer, Lung Cancer, Sarcoidosis, and Non-Small Cell Lung Cancer (NSCLC).

Her clinical research consists of co-authoring 15 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 3 articles in the study of EGFR Positive Lung Cancer.

Gender
Female

Locations

Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital
Izmir, Turkey
Other Locations
Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital, Izmir, Yenisehir, Turkey
Ege, Turkey
Yenisehir, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: April 26, 2021
Intervention Type: Drug
Study Phase: Phase 3

15 Total Publications

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 06, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Katgi's expertise for a condition
ConditionClose
        View All 8 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile